In the area of heart disease, Cytori Therapeutics (NASDAQ: CYTX) is sponsoring two European clinical trials that evaluate the use of adipose-derived stem and regenerative cells (ADRCs) to treat acute myocardial infarction and chronic myocardial ischemia.